drugset / Trial / NCT07104162
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
Phase 1
Completed
40 enrolled
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority · collabShionogi · collab
NaSequentialOpen-labelTreatment
Summary
A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment
Timeline
- Start
- 2025-09-16
- Primary completion
- 2026-09-04
- Completion
- 2026-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cefiderocol | Small molecule | — | Intravenous |
| Subject | Xeruborbactam | Small molecule | — | Intravenous |